Vivos Therapeutics, Inc. (VVOS) · Oct 15, 2026 · Acquisition

Vivos acquisition adds pseudohypoxia test, but closing remains conditional

$12M stock-for-assets transaction — 50% test IP plus 11% SOD stake for $12M preferred stock

Vivos’ acquisition brings a 50% test stake and potential Cleveland Clinic/AHA channels, but depends on approvals, validation and future dilution.

Vivos is a revenue-stage sleep-apnea device and healthcare-services company trying to scale through collaborations and acquisitions while reaching cash-flow positivity in late 2026 or early 2027. It is also addressing a Nasdaq stockholders’ equity deficiency; Nasdaq’s minimum requirement is $2.5 million.

The deal buys strategic optionality without using cash. Vivos will receive an 11% fully diluted stake in SOD plus 50% co-ownership of its pseudohypoxia test and related intellectual property in exchange for $12 million of newly created preferred stock. The structure preserves cash at a company that still expects to raise capital after resolving its listing issue, but it pays with a potentially substantial future equity claim.

ItemFiling figure
Preferred stock stated value$12 million (Certificate of Designations)
Fixed conversion price$0.15 per share (Certificate of Designations)
Maximum common shares before capUp to 80 million (Press Release)
Nasdaq exchange cap19.99% until stockholder approval (Certificate of Designations)
Pro forma stockholders’ equityApproximately $8 million (Pro Forma Balance Sheet)
Nasdaq minimum equity requirement$2.5 million (Nasdaq disclosure)

The immediate business impact is more access than revenue. The contemplated AHA and Cleveland Clinic Weston relationships could give Vivos distribution access to assisted-living and nursing-home populations and a potential program involving more than 2,000 existing CPAP patients. Vivos would retain 80% of contribution margin on its products, while test economics would be split 50/50. But those channels are still based on a term sheet and memorandum of understanding, not completed definitive commercial agreements.

The new diagnostic story is still unvalidated. The filing expressly says the transaction does not establish that the test predicts cancer or future chronic disease, and Vivos’ existing FDA clearances do not cover this test. Revenue therefore depends on clinical validation, regulatory status, testing volume, pricing and execution—not merely on owning half the intellectual property.

The Nasdaq benefit is accounting-dependent, not secured. The pro forma balance sheet shows approximately $8 million of equity, or $5.5 million above the $2.5 million requirement, but closing still requires an independent valuation, auditor concurrence, Streeterville’s consent and Nasdaq notification without objection. The filing also says Nasdaq has not yet confirmed compliance.

Dilution is deferred and capped, not eliminated. The preferred stock has no price reset or cash-settlement feature, which makes the structure less punitive than a floating-price financing, but it can convert into up to 80 million shares at $0.15. The 19.99% cap limits issuance until stockholders approve more, while the company is required to seek that approval alongside its reverse-split process.

Bottom line: This is a potentially meaningful expansion from sleep-apnea treatment into diagnostic testing and new distribution channels, while also offering a non-cash route toward Nasdaq compliance. For now, however, the value is contingent: the transaction is not yet closed, the channels are not definitive, and the test still needs clinical and commercial proof.

What to watch next

Closing confirmation and Nasdaq compliance review, October 15

Original filing on SEC EDGAR

More Vivos Therapeutics, Inc. news

Vivos acquisition adds pseudohypoxia test, but closing remains conditional | VVOS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.